跳至主要内容
临床试验/CTRI/2018/03/012644
CTRI/2018/03/012644已完成2 期

A Randomized Clinical End Point Study To Evaluate The Safety And Efficacy Of CLEARLIV Tablets In Patients With Alcoholic Liver Disease. - ALD

Apex Laboratories0 个研究点目标入组 24 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
24

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Chronic alcohol intake patients
  • 2.Serum AST &ALT is typically elevated to a level of 2â??6 times the upper limits of the normal.
  • 3.Negative pregnancy test for women in reproductive age (up to two weeks prior to the study)
  • 4.Negative for hepatitis B and C

排除标准

  • 1.Patients who have liver disease with the cause different from that of alcohol induced liver disease.
  • 2.Drug dependence
  • 3.A known hypersensitivity or allergy to any component of the drugs evaluated in the study.

研究者

发起方
Apex Laboratories

相似试验